{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:54Z","timestamp":1791912474614,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a chronic autoimmune disease caused by autoantibodies attacking the neuromuscular junction. Traditional treatments are often accompanied by side effects and lack specificity. Recent studies have found that Th17 cells and the inflammatory factor IL-17, which they secrete, play a key role in the pathogenesis of MG and have become potential therapeutic targets. Secukinumab, an IL-17 inhibitor, has shown efficacy in other autoimmune diseases, but its role in MG remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the clinical efficacy and immunomodulatory effects of secukinumab in acetylcholine receptor antibody-positive generalized MG (AChR+ gMG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective study, 29 AChR+ gMG patients received subcutaneous secukinumab (150\u202fmg weekly for 4\u202fweeks, then monthly for 24\u202fweeks). Clinical outcomes (QMG, MG-QOL15, MG-ADL scores), AChR antibody titers, Th17 cell frequency, and IL-17 levels were assessed at baseline and during treatment. Correlations between biomarkers and clinical improvements were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      By week 24, secukinumab treatment led to significant reductions in disease severity scores (QMG: 60.7%; MG-QOL15: 58.3%; MG-ADL: 64.1%) and AChR antibody levels (69.23%). Th17 cell frequency and IL-17 levels decreased by 68 and 84.47%, respectively. Strong baseline correlations were observed between IL-17, Th17, and clinical scores (\n                      <jats:italic>r<\/jats:italic>\n                      \u202f=\u202f0.642\u20130.970,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), with progressive uncoupling of these relationships during treatment. No severe adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab demonstrated rapid and sustained clinical benefits in AChR+ gMG, linked to suppression of the Th17\/IL-17 pathway. These findings highlight IL-17 inhibition as a promising targeted strategy for MG. Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1642938","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:51Z","timestamp":1761106671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuangmei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e179742","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1110499","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14737175.2023.2207739","article-title":"Conventional and emerging treatments and controversies in myasthenia gravis","volume":"23","author":"Evoli","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e 1585","DOI":"10.1002\/wsbm.1585","article-title":"Evolution of precision oncology-guided treatment paradigms","volume":"15","author":"Das Gupta","year":"2023","journal-title":"WIREs Mech Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1404191","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in myasthenia gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal antibody-based therapies for myasthenia gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"Bio Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunore -gulatory mechanisms in myasthenia gravis: role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"578129","DOI":"10.1016\/j.jneuroim.2023.578129","article-title":"Thymoma patients with or without myasthenia gravis have increased Th17 cells, IL-17 production and ICOS expression","volume":"381","author":"Cebi","year":"2023","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s10072-023-06796-8","article-title":"Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?","volume":"44","author":"Kim","year":"2023","journal-title":"Neurol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/imm.12322","article-title":"Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses","volume":"143","author":"Yao","year":"2014","journal-title":"Immunology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1280029","DOI":"10.3389\/fimmu.2024.1280029","article-title":"Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","article-title":"Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab","volume":"8","author":"Spindeldreher","year":"2018","journal-title":"Dermatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.55563\/clinexprheumatol\/rl668e","article-title":"Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary","volume":"39","author":"Fonti","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"715036","DOI":"10.3389\/fimmu.2021.715036","article-title":"Clinical efficacy and safety of Eculizumab for treating myasthenia gravis","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2018.11.005","article-title":"Il-23\/Th17 cell pathway: a promising target to alleviate thymic inflammation maintenance in myasthenia gravis","volume":"98","author":"Villegas","year":"2019","journal-title":"J Autoimmun"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-\u03b1","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J Autoimmun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12974-023-02691-3","article-title":"Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis","volume":"20","author":"Villegas","year":"2023","journal-title":"J Neuroinflammation"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"108492","DOI":"10.1016\/j.clim.2020.108492","article-title":"Circulating Th1\/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients","volume":"218","author":"Ma","year":"2020","journal-title":"Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molimm.2021.02.011","article-title":"Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis","volume":"133","author":"Chen","year":"2021","journal-title":"Mol Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"577279","DOI":"10.1016\/j.jneuroim.2020.577279","article-title":"Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis","volume":"345","author":"Li","year":"2020","journal-title":"J Neuroimmunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejca.2020.10.006","article-title":"Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity","volume":"141","author":"Mazzarella","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","article-title":"Current drug treatment of myasthenia gravis","volume":"36","author":"Vanoli","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experim -ental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"578464","DOI":"10.1016\/j.jneuroim.2024.578464","article-title":"Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients","volume":"396","author":"Li","year":"2024","journal-title":"J Neuroimmunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizu-mab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1642938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:51Z","timestamp":1761106671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1642938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":31,"alternative-id":["10.3389\/fneur.2025.1642938"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1642938","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1642938"}}